Drug Type Small molecule drug |
Synonyms IB-1001, IB1001 |
Target |
Mechanism calcium channel modulators(Calcium Channel modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationPriority Review (US), Orphan Drug (US) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Niemann-Pick Disease, Type C | NDA/BLA | US | 26 Mar 2024 | |
Ataxia Telangiectasia | Phase 2 | US | 08 Jan 2020 | |
Ataxia Telangiectasia | Phase 2 | DE | 08 Jan 2020 | |
Ataxia Telangiectasia | Phase 2 | ES | 08 Jan 2020 | |
Ataxia Telangiectasia | Phase 2 | GB | 08 Jan 2020 | |
Sandhoff Disease | Phase 2 | US | 07 Jun 2019 | |
Sandhoff Disease | Phase 2 | DE | 07 Jun 2019 | |
Sandhoff Disease | Phase 2 | ES | 07 Jun 2019 | |
Sandhoff Disease | Phase 2 | GB | 07 Jun 2019 | |
Tay-Sachs Disease | Phase 2 | US | 07 Jun 2019 |
NCT03759665 (Accesswire) Manual | Phase 2 | 30 | jvvbwxmngd(vbikigsozy) = statistically significant change. 90% CI: 0.00, 1.50, p-value = 0.039 upgzdccopg (inwcupayqs ) View more | Positive | 14 Sep 2021 | ||
Phase 2 | 32 | N-acetyl-L-leucine | nvkjpgzykq(qycerfbxqv) = NALL met the CI-CS primary endpoint (mean difference 0.86, SD = 2.52, 90% CI 0.25, 1.75, p = 0.029) wnkimusvlr (rdfxyotkgk ) | Positive | 13 Aug 2021 | ||
Phase 3 | 9 | mmsiithbjk(xxibrnwole) = bzhbbqtkyf qowkwsdyxu (srvohlwzpb, ockyfezawb - mxysujaqfg) View more | - | 11 Apr 2019 |